(Q52893080)

9 May 2018

title

Evaluation of the potential of PET-MRI fusion for detection of liver metastases in patients with neuroendocrine tumours. (English)

1 reference

9 May 2018

5

Bernd Hamm

1 reference

9 May 2018

Nils F Schreiter

1

1 reference

9 May 2018

Munenobu Nogami

2

1 reference

9 May 2018

Ingo Steffen

3

1 reference

9 May 2018

Ulrich-Frank Pape

4

1 reference

9 May 2018

Winfried Brenner

6

1 reference

9 May 2018

Rainer Röttgen

7

1 reference

9 May 2018

language of work or name

English

0 references

publication date

9 September 2011

1 reference

9 May 2018

published in

European Radiology

1 reference

9 May 2018

volume

22

1 reference

9 May 2018

issue

2

1 reference

9 May 2018

page(s)

458-467

1 reference

9 May 2018

https://scigraph.springernature.com/pub.10.1007/s00330-011-2266-4

exact match

0 references

cites work

Consensus guidelines for the management of patients with liver metastases from digestive (neuro)endocrine tumors: foregut, midgut, hindgut, and unknown primary

1 reference

https://api.crossref.org/works/10.1007%2FS00330-011-2266-4

Hepatic ablation for neuroendocrine tumor metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00330-011-2266-4

Treatment of liver metastases from neuroendocrine tumours in relation to the extent of hepatic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00330-011-2266-4

Prognostic factors in patients with endocrine tumours of the duodenopancreatic area

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00330-011-2266-4

Surgical treatment of neuroendocrine metastases to the liver: a plea for resection to increase survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00330-011-2266-4

Hepatic surgery for metastases from neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00330-011-2266-4

Hepatic neuroendocrine metastases: does intervention alter outcomes?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00330-011-2266-4

MR imaging in patients with suspected liver metastases: value of liver-specific contrast agent Gd-EOB-DTPA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00330-011-2266-4

Improved detection of focal liver lesions at MR imaging: multicenter comparison of gadoxetic acid-enhanced MR images with intraoperative findings

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00330-011-2266-4

Comparison of 68Ga-DOTATOC PET and 111In-DTPAOC (Octreoscan) SPECT in patients with neuroendocrine tumours.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00330-011-2266-4

Evaluation of Positron Emission Tomography Imaging Using [68Ga]-DOTA-D Phe1-Tyr3-Octreotide in Comparison to [111In]-DTPAOC SPECT. First Results in Patients with Neuroendocrine Tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00330-011-2266-4

Combined PET/MRI: a new dimension in whole-body oncology imaging?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00330-011-2266-4

Value of retrospective fusion of PET and MR images in detection of hepatic metastases: comparison with 18F-FDG PET/CT and Gd-EOB-DTPA-enhanced MRI.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00330-011-2266-4

Whole-body MRI and FDG PET fused images for evaluation of patients with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00330-011-2266-4

Additional value of MR/PET fusion compared with PET/CT in the detection of lymph node metastases in cervical cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00330-011-2266-4

Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00330-011-2266-4

Liver metastases in candidates for hepatic resection: comparison of helical CT and gadolinium- and SPIO-enhanced MR imaging.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00330-011-2266-4

Diagnostic imaging of colorectal liver metastases with CT, MR imaging, FDG PET, and/or FDG PET/CT: a meta-analysis of prospective studies including patients who have not previously undergone treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00330-011-2266-4

The use of 18F-FDG PET/CT in colorectal liver metastases--comparison with CT and liver MRI.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00330-011-2266-4

Imaging appearances of metastases from neuroendocrine tumours of the pancreas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00330-011-2266-4

Imaging of liver metastases: MRI.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00330-011-2266-4

Efficacy and safety of MR imaging with liver-specific contrast agent: U.S. multicenter phase III study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00330-011-2266-4

Liver tumor characterization: comparison between liver-specific gadoxetic acid disodium-enhanced MRI and biphasic CT--a multicenter trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00330-011-2266-4

Diffusion weighted imaging in the liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00330-011-2266-4

Impact of Multiphase 68Ga-DOTATOC-PET/CT on therapy management in patients with neuroendocrine tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00330-011-2266-4

The impact of 68Ga-DOTATOC positron emission tomography/computed tomography on the multimodal management of patients with neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00330-011-2266-4

Somatostatin receptor scintigraphy versus chromogranin A assay in the management of patients with neuroendocrine tumors of different types: clinical role

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00330-011-2266-4

Concordance between results of somatostatin receptor scintigraphy with 111In-DOTA-DPhe 1-Tyr 3-octreotide and chromogranin A assay in patients with neuroendocrine tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00330-011-2266-4

Association of somatostatin receptor 2 immunohistochemical expression with [111In]-DTPA octreotide scintigraphy and [68Ga]-DOTATOC PET/CT in neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00330-011-2266-4

ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: somatostatin receptor imaging with (111)In-pentetreotide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00330-011-2266-4

Whole-body PET/MRI: the future in oncological imaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00330-011-2266-4

PET/MRI: a different spin from under the rim.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00330-011-2266-4

Imaging of neuroendocrine tumours (CT/MR/US).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00330-011-2266-4

Diagnosis of neuroendocrine tumours by retrospective image fusion: is there a benefit?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00330-011-2266-4

Detection of unknown primary neuroendocrine tumours (CUP-NET) using (68)Ga-DOTA-NOC receptor PET/CT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00330-011-2266-4

Endocrine pancreatic tumors: factors correlated with survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00330-011-2266-4

68Ga-DOTA-Tyr3-Octreotide PET in Neuroendocrine Tumors: Comparison with Somatostatin Receptor Scintigraphy and CT

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00330-011-2266-4

Prognostic factors and survival in endocrine tumor patients: comparison between gastrointestinal and pancreatic localization

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00330-011-2266-4

Detection, classification, and characterization of focal liver lesions: Value of diffusion-weighted MR imaging, gadoxetic acid-enhanced MR imaging and the combination of both methods

21 January 2018

1 reference

12 December 2020

MRI of carcinoid tumors: spectrum of appearances in the gastrointestinal tract and liver

1 reference

12 December 2020

Carcinoid tumours. Frequency in a defined population during a 12-year period

1 reference

12 December 2020

Somatostatin receptor scintigraphy in liver metastasis detection from gastroenteropancreatic neuroendocrine tumors.

1 reference

12 December 2020

Processing of generator-produced 68Ga for medical application.

1 reference

12 December 2020

Carcinoid metastases to the liver: role of triple-phase helical CT

1 reference

12 December 2020

Isolated liver metastases from neuroendocrine tumors: does resection prolong survival?

1 reference

12 December 2020

Liver resection (and associated extrahepatic resections) for metastatic well-differentiated endocrine tumors: A 15-year single center prospective study

1 reference

12 December 2020

Retrospective digital image fusion of multidetector CT and 18F-FDG PET: clinical value in pancreatic lesions--a prospective study with 104 patients.

1 reference

12 December 2020

Liver tumors: comparison of MR imaging with Gd-EOB-DTPA and Gd-DTPA

1 reference

12 December 2020

Diagnosis of liver metastases: can diffusion-weighted imaging (DWI) be used as a stand alone sequence?

1 reference

12 December 2020

10.1007/S00330-011-2266-4

Identifiers

DOI

1 reference

9 May 2018

1 reference

9 May 2018